GSK 2245035

Drug Profile

GSK 2245035

Alternative Names: GSK-2245035

Latest Information Update: 10 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator GlaxoSmithKline
  • Class
  • Mechanism of Action Immunomodulators; Interferon alfa 2a stimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Allergic rhinitis

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Allergic asthma in Germany, United Kingdom (Intranasal) (EudraCT2015-005645-31) (NCT02833974)
  • 12 Jul 2016 GlaxoSmithKline plans a phase II trial for Allergic asthma in Germany (Intranasal) (NCT02833974)
  • 01 Aug 2015 GlaxoSmithKline completes a phase II follow-up trial for Allergic asthma and Allergic rhinitis in Canada (NCT02446613)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top